Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia

NCT00352677 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia

Interventions

DRUG: INNO-406

Sponsor

CytRx